Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation
- PMID: 10319819
- DOI: 10.1016/s0092-8674(00)80748-5
Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation
Abstract
The amyloid-beta precursor protein (APP) is directly and efficiently cleaved by caspases during apoptosis, resulting in elevated amyloid-beta (A beta) peptide formation. The predominant site of caspase-mediated proteolysis is within the cytoplasmic tail of APP, and cleavage at this site occurs in hippocampal neurons in vivo following acute excitotoxic or ischemic brain injury. Caspase-3 is the predominant caspase involved in APP cleavage, consistent with its marked elevation in dying neurons of Alzheimer's disease brains and colocalization of its APP cleavage product with A beta in senile plaques. Caspases thus appear to play a dual role in proteolytic processing of APP and the resulting propensity for A beta peptide formation, as well as in the ultimate apoptotic death of neurons in Alzheimer's disease.
Similar articles
-
beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer's disease mutations.Brain Res Mol Brain Res. 2001 Dec 16;97(1):103-13. doi: 10.1016/s0169-328x(01)00294-7. Brain Res Mol Brain Res. 2001. PMID: 11744168
-
Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation.J Neurosci Res. 2001 Apr 15;64(2):183-92. doi: 10.1002/jnr.1064. J Neurosci Res. 2001. PMID: 11288146
-
Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury.J Neurotrauma. 2002 May;19(5):601-14. doi: 10.1089/089771502753754073. J Neurotrauma. 2002. PMID: 12042095
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
Secretases as targets for the treatment of Alzheimer's disease: the prospects.Lancet Neurol. 2002 Nov;1(7):409-16. doi: 10.1016/s1474-4422(02)00188-6. Lancet Neurol. 2002. PMID: 12849363 Review.
Cited by
-
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer's Disease.Int J Mol Sci. 2024 Oct 11;25(20):10964. doi: 10.3390/ijms252010964. Int J Mol Sci. 2024. PMID: 39456746 Free PMC article. Review.
-
Depletion of TDP-43 exacerbates tauopathy-dependent brain atrophy by sensitizing vulnerable neurons to caspase 3-mediated endoproteolysis of tau in a mouse model of Multiple Etiology Dementia.bioRxiv [Preprint]. 2024 Jun 29:2024.06.26.600814. doi: 10.1101/2024.06.26.600814. bioRxiv. 2024. PMID: 38979270 Free PMC article. Preprint.
-
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease.Acta Neuropathol. 2024 Jun 9;147(1):96. doi: 10.1007/s00401-024-02747-5. Acta Neuropathol. 2024. PMID: 38852117 Free PMC article. Review.
-
Hypocretin (Orexin) Replacement Therapies.Med Drug Discov. 2020 Dec;8:100070. doi: 10.1016/j.medidd.2020.100070. Epub 2020 Oct 17. Med Drug Discov. 2020. PMID: 38738170 Free PMC article.
-
Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer's disease, and epilepsy.Front Neurol. 2024 Jan 5;14:1287545. doi: 10.3389/fneur.2023.1287545. eCollection 2023. Front Neurol. 2024. PMID: 38249745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
